Raymond James Reiterates Strong Buy Rating on Liquidia Technologies (LQDA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Raymond James Reiterates Strong Buy Rating on Liquidia Technologies (LQDA)
October 8, 2024 6:09 AM EDT
LifeSci Capital analyst Cory Jubinville reiterated an Outperform rating and $30.00 price target on Liquidia Technologies (NASDAQ: LQDA)
The analyst comments "As we highlighted in our recent initiation (link here), the commercial launch of Liquidias (Nasdaq: LQDA) Yutrepia has been held back due to patent suits brought forward by United Therapeutics (Nasdaq: UTHR) regarding two key patents: 793 and 327. The 793 patent had previously been deemed invalid by the Federal Circuit for... More
October 7, 2024 1:01 PM EDT
BTIG analyst Julian Harrison reiterated a Buy rating and $25.00 price target on Liquidia Technologies (NASDAQ: LQDA).
The analyst comments "As we expected, the Supreme Court of the United States has denied UTHR's (Neutral) writ of certiorari request to challenge the prior invalidation of... More
